Hemophilia A and B Clinical Trial
Official title:
Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
| Verified date | November 2020 |
| Source | Bayer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study was to assess the safety and tolerability of multiple doses of a human monoclonal antibody (BAY1093884) given under the skin in subjects with hemophilia A or B. This antibody was intended to protect from bleeds by inhibiting a substance (Tissue Factor Pathway Inhibitor, TFPI) that reduces the ability of the body to form blood clots.
| Status | Terminated |
| Enrollment | 24 |
| Est. completion date | October 15, 2019 |
| Est. primary completion date | October 15, 2019 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Male severe hemophilic patients with undetectable FVIII activity <1% or FIX activity <2%, with or without inhibitors (any titer) are eligible. - Subjects with a past history of inhibitors (any inhibitor titer) are eligible. - Age =18 years. - Documentation of =4 bleeding episodes (any type or location of bleeds, treated or not) within the 6 months prior to screening. - For subjects on prophylaxis: Willingness to interrupt ongoing prophylaxis. - For subjects on immune tolerance induction (ITI): Willingness to interrupt ongoing ITI. Exclusion Criteria: - History of any other coagulation disorder (particularly disseminated intravascular coagulopathy or combined FVIII/FV deficiency) or platelet disorder. - History of diseases related to venous thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis, thrombophlebitis) or thrombotic microangiopathy. - Risk factors for venous or arterial diseases (e.g., uncontrolled hypertension, uncontrolled diabetes). - History of cardiac, coronary and/or arterial peripheral atherosclerotic disease - Platelet count <100,000/µL. - Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of <200/mm^3 |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Fiona Stanley Hospital | Murdoch | Western Australia |
| Austria | Universitätsklinikum AKH Wien | Wien | |
| Bulgaria | Medical centre Hipokrat - N EOOD | Plovdiv | |
| Bulgaria | SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD | Sofia | |
| Bulgaria | MHAT Sveta Marina EAD | Varna | |
| France | Hôpital Louis Pradel - Bron | Bron | |
| France | Hôpital Robert Debré - Reims Cedex | Reims Cedex | |
| Hungary | Pecsi Tudomanyegyetem Klinikai Kozpont | Pecs | |
| Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano | Lombardia |
| Japan | Hiroshima University Hospital | Hiroshima | |
| Japan | Ogikubo Hospital | Suginami | Tokyo |
| Korea, Republic of | Eulji University Hospital | Daejeon | |
| New Zealand | Haematology Service, Canterbury Health Laboratories | Christchurch | |
| Taiwan | Changhua Christian Hospital | Changhua | |
| United Kingdom | University Hospital of Wales | Cardiff | |
| United Kingdom | Royal Free Hospital | London | |
| United Kingdom | Manchester Royal Infirmary | Manchester |
| Lead Sponsor | Collaborator |
|---|---|
| Bayer |
Australia, Austria, Bulgaria, France, Hungary, Italy, Japan, Korea, Republic of, New Zealand, Taiwan, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants With Drug-related Treatment-emergent Adverse Events | An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs occurring after the first administration of study drug and up to and including 30 days after the last administration of study drug were defined as treatment-emergent AEs (TEAEs). Drug-related TEAEs were TEAEs that had "reasonable causal relationship" to the study treatment decided by the investigators. | After the first administration of study drug and up to and including 30 days after the last administration of study drug, with an average of 183 days | |
| Primary | Number of Participants With Serious Treatment-emergent Adverse Events | A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. SAEs occurring after the first administration of study drug and up to and including 30 days after the last administration of study drug were defined as serious treatment-emergent AEs (TESAEs). Drug-related TESAEs were TESAEs that had "reasonable causal relationship" to the study treatment decided by the investigators. | After the first administration of study drug and up to and including 30 days after the last administration of study drug, with an average of 183 days | |
| Primary | Number of Participants With Treatment-emergent Adverse Events of Special Interest | Any thromboembolic or thrombotic microangiopathic event or any hypersensitivity reaction was an adverse event of special interest (AESI). AESIs occurring after the first administration of study drug and up to and including 30 days after the last administration of study drug were defined as treatment-emergent AESIs. | After the first administration of study drug and up to and including 30 days after the last administration of study drug, with an average of 183 days | |
| Primary | Number of Participants With Clinically Relevant Abnormalities in Laboratory Values | "Clinically relevant "implied the presence of a clinical sign or symptom that required medical action. | After the first administration of study drug and up to and including 30 days after the last administration of study drug, with an average of 183 days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04055051 -
ATHN 11: Liver Transplantation Outcomes Study
|
||
| Completed |
NCT02776826 -
World Bleeding Disorders Registry Pilot Study
|
N/A |